Multimmune
Company Details
Status: Private
Employees: 1-10
Location:
Munich, Bayern, Germany
Type:
sample
sample
Technology:
sample
sample
About: multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform on the basis of the founding scientists' (Professor Gabriele Multhoff, Dr Claus Botzler) discovery that cell surface-bound Hsp70 is uniquely expressed on a large proportion of cancers (~50-75%), but not on healthy cells. This makes this form of Hsp70 an excellent and broadly-applicable molecule on which to base the development of innovative therapeutics and diagnostics (theranostics).
Based on its discovery of membrane Hsp70, multimmune has succeeded in developing a powerful pipeline of cancer therapeutics. ENKASTIM allows, for the first time, a unique and specific activation of human natural killer (NK) cells which are programmed to recognise and kill cancers expressing membrane Hsp70 via the release of a cytotoxic molecule called granzyme B. These cells destroy tumors and metastases that are invisible to the cell killing (cytolytic) consequences of more conventional T cell-based immunotherapies.
Hsp70-expressing tumors can also be targeted using therapeutics based on a unique monoclonal antibody which can detect the membrane form of Hsp70.
multimmune's lead diagnostic candidate is the patented and CE-marked Hsp70-exo enzyme immunoassy (ELISA) which detects lipid-associated Hsp70 in the peripheral circulation, levels of which can be used to detect the presence of tumors expressing membrane Hsp70, as well as monitoring therapeutic response and disease recurrence.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Multimmune | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.